Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
Definitive Healthcare Appoints Kevin Coop as CEO for Next Phase of Company’s Growth
-
Gabelli Funds to Host 16th Annual Media & Entertainment Symposium Thursday, June 6, 2024
-
LevLane Advertising Wins PRSA Anvil Award for Best Feature Article Addressing Bias Against Use of Biological Terms in Women's Health Marketing and Advertising
-
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Absci to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
-
Decisions of the Annual General Meeting of AS Pro Kapital Grupp shareholders
-
Wood Mackenzie names new leader for Consulting
-
UEFA Grants Exclusive Rights to Hisense as Official VAR Screen Provider for UEFA EURO 2024™
-
Vista Outdoor Rejects Unsolicited Indication of Interest from MNC Capital
-
Alliance Trust PLC - Net Asset Value
-
Vista Outdoor Confirms CSG Increases Purchase Price for The Kinetic Group Business by $50 Million to $1.96 Billion
-
Granite Creek Copper Announces 2024 Exploration Program at Carmacks Project in Yukon, Canada
-
Electric Royalties Provides Seven Updates on Its Lithium, Graphite, Copper, Nickel, and Tin Royalties
-
NeuralAI Launches AI 3D Asset Generator with TAO Bittensor Subnet: Transforming 3D Model Creation for Games and Beyond
-
Shoulder Innovations Unveils New Humeral Preoperative Planning Feature with ProVoyance Shoulder
-
Affinia Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference
-
CAE, INC. ALERT: CAE, Inc. Falls after Announcing Impairment Charges (NYSE: CAE) – Investors are Encouraged to Contact BFA Law About Your Rights
-
Dopavision Announces Topline Results in Clinical Trial of Targeted Photobiomodulation Approach for Progressive Myopia
-
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermat
-
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis
-
Entourage Health Reports First Quarter 2024 Financial Results: Achieves $16.4 Million in Total Revenue and Marks First EBITDA-Positive Quarter
-
Inter&Co doubles down on SMEs through acquisition of Granito
-
Unyted and INU Launch INUVERSE: The Future of Immersive Education
-
Inter&Co doubles down on SMEs through acquisition of Granito
-
T-Mobile to Acquire UScellular Wireless Operations and Deliver Exceptional Value, a Superior 5G Experience and Unparalleled Benefits to Millions of Customers
-
Sterling Metals Announces Mark Goodman as Chairman and Provides Corporate Update
-
U.S. Antimony (UAMY) Announces Appointment of Melissa Pagen as Senior Vice President of Corporate Development and Governmental Relations
-
Ivanhoe Mines Completes Construction of Kamoa-Kakula's Phase 3 Concentrator Ahead of Schedule and on Budget
-
Fathom Continues to Intersect High-Grade Mineralization and Expand the Historic Gochager Lake Deposit in All Directions
-
Alta Showcases Ability to Transform MMA Fans into Participants through Partnership with City Kickboxing in New Zealand
-
CEO.CA's Inside the Boardroom: Latest News From Junior Mining CEOs
-
ARway.ai Closes Acquisition of Map Dynamics, Adding $1.2M Revenue and $250K EBITDA in All-Stock Deal
-
WIDEOPENWEST ALERT: WideOpenWest’s $4.80 Per Share Offer from DigitalBridge is Under Investigation (NYSE: WOW) – Contact BFA Law to Discuss How this Impacts You
-
Nextech3D.ai Announces The Closing of Map Dynamics Sale to ARway.ai To Focus on Patented High-Margin Generative AI-powered 3D Modeling Technology
-
RE Royalties Ltd. to Present at Canadian Climate Investor Conference
-
Rekor Introduces Cutting-Edge Cybersecurity Capabilities to Help State Dots Protect National Transportation Infrastructure
-
Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio's Lead Compound PH-762
-
SQUARESPACE ALERT: Squarespace’s $44 Per Share Buyout Offer From Permira is Under Investigation (NYSE: SQSP) - Contact BFA Law to Discuss How this Impacts You
-
Factor Bioscience Successfully Defends Three U.S. Patents Covering Foundational Methods for Therapeutic Gene Editing
-
ITURAN LOCATION AND CONTROL LTD ANNOUNCES DISTRIBUTION OF A $8 MILLION DIVIDEND
-
Danaos Corporation Reports First Quarter Results for Period Ended March 31, 2024
-
Yotvata Dairy Farm Invests in Mileutis to Improve Milk Quality
-
TransDigm Announces Acquisition of Raptor Scientific
-
Yorbeau Consolidates Interest in Its Beschefer Property
-
TDS Board Announces Unanimous Support for Sale of UScellular's Wireless Operations and Select Spectrum Assets to T-Mobile
-
UScellular and TDS Announce Sale of Wireless Operations and Select Spectrum Assets to T-Mobile for Approximately $4.4 Billion in Cash and Assumed Debt
-
Opthea Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD
-
TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
-
Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD
-
Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis
